• M D Caramia, M G Palmieri, M T Desiato, C Iani, A Scalise, S Telera, and G Bernardi.
• Clinica Neurologica, Department of Neuroscience, Università di Roma Tor Vergata, and the IRCCS, S. Lucia, Rome, Italy. mwjones@ats.it
• Neurology. 2000 Jan 11; 54 (1): 58-64.

ObjectiveTo reverse the profile of abnormal intracortical excitability in patients with ALS by administering drugs that promote GABAergic transmission.BackgroundTranscranial magnetic stimulation (TMS) has revealed abnormalities of cortical inhibition in ALS, a reduction of the silent period, and the absence of intracortical inhibition normally occurring in response to paired TMS. Impaired inhibitory transmission could play a role in the physiopathology of this illness.MethodsUsing paired TMS with conditioning stimuli from 1-to-6-msec-interstimulus intervals, we investigated 16 patients with ALS. The protocol included: (1) the "drug-free" profile of paired TMS; (2) paired TMS 30 minutes after the intake of diazepam (3.5 mg); (3) paired TMS after 3 weeks' treatment with gabapentin (GBP) (600 mg/day) or riluzole (50 mg/twice a day).ResultsIntracortical inhibition is lost in patients with ALS, and this abnormal profile is reversed by diazepam or sustained treatment with GBP. We also noted that motor-evoked potential amplitudes to single stimuli increased (p<0.01) after diazepam and GBP.ConclusionsThe demonstration of pharmacologic reversal of hyperexcitability in patients with ALS makes a potentially significant contribution toward understanding the pathophysiology of a disease that has so far eluded an effective cure.

38 keywords...

hide…